E-Learning

Megacap Tech Stocks Have Gotten Too Big for Nasdaq 100 Again

(Bloomberg) -- Only a year after having their size clipped in the Nasdaq 100 because they got too big, the world’s largest technology companies may face another pruning when the marquee benchmark rebalances this week.Most Read from BloombergHow California Sees the World, and ItselfHong Kong's Expat Party Hub Reshaped by Chinese InfluxLondon’s Tube Fares Are Set to Rise by 4.6% Next YearAt issue are regulations designed to cap the influence of the biggest members in the gauge — rules that have be

Read more

Fed Meetings Made Stock Traders Richer In 2024: Could Wednesday Bring Last Big Rally?

The U.S. stock market has generally delivered solid gains around Federal Reserve meetings in 2024, signaling investor optimism as the central bank prepares for its final policy decision of the year on Wednesday. An investor adopting a short-term long strategy — buying the S&P 500 index at market close the day before a Fed meeting and selling at the close the day after — would have realized a median return of 1.1% over the last seven meetings. According to data compiled by Seasonax, this strategy

Read more

Australia Is New Bond Market Favorite for JPMorgan Asset Management

(Bloomberg) -- The great run in European government bonds is coming to an end, according to a portfolio manager at J.P. Morgan Asset Management, who is now betting Australia will be the next market to outperform.Most Read from BloombergHow California Sees the World, and ItselfHong Kong's Expat Party Hub Reshaped by Chinese InfluxLondon’s Tube Fares Are Set to Rise by 4.6% Next YearKim Crawford said there is little room for further gains in Europe compared to peers given swap markets are fairly p

Read more

Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside

Cantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products. The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatology conditions. Cantor highlights that th

Read more